The nation of Zimbabwe has rejected a substantial American health deal valued at $367m (£272m) over five years due to Washington's demand for confidential biological samples.
This move was revealed following a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government representative later clarified that the US was seeking health data for research and profit but was not willing to guarantee the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged further talks to reach a agreement acceptable to all parties so the nation's critical HIV programme can be sustained.
Broader Implications
Zimbabwe's decision follows a comparable situation in Kenya, where a high court halted a related health funding agreement following concerns were filed about the safety of Kenyans' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was pursuing government-to-government agreements to enhance transparency and accountability.
According to reports, 16 African countries have so far agreed to these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be available to our population should a future disease outbreak arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting systems already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This framework is intended to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation could be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but suggested that talks must proceed given that much of the nation's HIV programmes were funded by foreign aid.
"Where technical issues arise, such as those relating to information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it added.
This impasse highlights the ongoing tensions between receiving crucial international aid and safeguarding a country's data in an increasingly data-driven world.